Abstract
No public abstract is available from the verified source records.
Open public full textRights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureKatie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith F. Abu-Zeinah
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Myelofibrosis and survival prognostic models: a journey between past and future
10.3390/jcm12062188 · 2023
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story
10.1182/bloodadvances.2022007230 · 2022
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
10.1038/s41375-019-0638-y · 2020
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
10.1038/s41375-021-01183-8 · 2021
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
10.1038/s41375-023-02008-6 · 2023
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
10.1182/blood-2010-11-320069 · 2011
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis
10.1002/cncr.30679 · 2017
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome
10.1182/bloodadvances.2022007128 · 2022
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
10.1182/blood-2012-05-432989 · 2013
Confidence 92%
datacite
Confidence 0%
Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib
10.1080/17474086.2017.1284583 · 2017
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
10.3324/haematol.2019.235648 · 2020
Final results of ruxopeg, a phase 1/2 adaptive randomized trial of ruxolitinib (Rux) and pegylated interferon alpha (IFNa) 2a in patients with myelofibrosis (MF)
10.1182/blood-2022-156389 · 2022
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022
MIPSS70+ version 2.0: mutation and karyotype-enhanced International Prognostic Scoring system for primary myelofibrosis
2018
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
10.1182/blood-2013-03-488098 · 2013
No additional external references are available.